Lakewood-Amedex Biotherapeutics Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 48/100
What the filing says
On September 22, 2026, shareholders approved Amendment No. 1 to the 2020 Equity Incentive Plan, increasing authorized shares from 183,505 to 400,000 (a 216,495-share or 118% increase). The amendment, approved by the Board on July 20, 2026, raises both the aggregate shares available for awards and the cap on Incentive Stock Options to 400,000 shares. No pricing, vesting schedules, or recipient details are disclosed in this exhibit.
Why this rating
Material equity dilution (118% increase) for tiny $5M-asset company signals runway extension via employee incentives, but administrative nature and lack of financial/operational impact warrant moderate scoring.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.